About VLA2001 VLA2001 is currently the only adjuvant vaccine candidate inactivated for the entire virus in COVID-19 clinical trials in Europe. It is intended for active immunization of at-risk populations to prevent promotion and symptomatic infection with COVID-19 during the ongoing pandemic and possibly later for routine vaccination, including treatment of new variants. VLA2001 may also be suitable for the increase, as repeated booster injections have been shown to work well with inactivated vaccines of the entire virus. VLA2001 is produced on Valneva`s established Vero cellular platform and uses Valneva`s licensed IXIARO® Japanese encephalitis vaccine manufacturing technology. VLA2001 consists of whole inactivated sarS-CoV-2 virus particles with high density of S proteins, in combination with two excipients, alum and CpG 1018. This adjuvant combination consistently induced higher antibody levels than pure alum formulations in preclinical experiments and showed a change in the immune response to Th1. CpG 1018 adjuvant, supplied by Dynavax Technologies Corporation (Nasdaq: DVAX), is a component of the HEPLISAV-B vaccine® approved by the U.S. FDA and EMA. The manufacturing process of VLA2001, which has already been extended to the final industrial scale, involves chemical inactivation to preserve the native structure of the S protein. VLA2001 should meet the standard requirements of the cold chain (2 to 8 degrees Celsius).
Forward-Looking Statements This press release contains certain forward-looking statements regarding Valneva`s operations, including progress, timing, design, data readings, expected results and completion of clinical trials for VLA2001. Although Valneva`s actual results or developments are consistent with the forward-looking statements contained in this press release, such results or developments of Valneva may not be indicative of future results. In some cases, you may identify forward-looking statements by words such as “could”, “should”, “may”, “expects”, “anticipates”, “believes”, “intends”, “estimates”, “aims”, “targets” or similar words. These forward-looking statements are based on Valneva`s current expectations as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that could cause actual results, performance or achievements to differ materially from future results, performance or achievements expressed or implied by such forward-looking statements. can be brought. In particular, Valneva`s expectations could be affected, among other things, by uncertainties related to vaccine development and manufacturing, unexpected results of clinical trials, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, the ability to obtain or maintain patents or other protected intellectual property protections. the termination of existing contracts, including, but not limited to, HMG`s supply agreement, and the impact of the COVID-19 pandemic, the occurrence of which could significantly affect Valneva`s business, financial condition, prospects and results of operations. Given these risks and uncertainties, there can be no assurance that any forward-looking statements made in this presentation will be effectively implemented. Valneva provides the information contained in this press release as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The COVID-19 Vaccines Market Dashboard provides transparency and visibility to gain insights into the COVID-19 vaccine market. In this first version, the tool provides an overview of the vaccines under development, their stage of development and their technological platforms.
In addition, information on globally reported production capacity as well as bilateral and multilateral supply agreements and publicly announced prices will be provided. Moderna`s mRNA platform builds on continuous advances in the basic and applied science of mRNA, delivery technology and manufacturing, and has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has been recognized by Science as one of the top biopharmaceutical employers for the past seven years. For more information, see www.modernatx.com. CAMBRIDGE, Mass., December 10, 2021–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MNR), a pioneering biotechnology company in messenger RNA (mRNA) therapies and vaccines, today announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to deliver 20 million doses to COVAX by December 31. December 2021 for a total of 54 million doses to be made available to COVAX in 2021. Deliveries to COVAX Advance Market Commitment (AMC) countries have already begun.
In addition, Moderna recently announced an agreement that will allow countries in the European Union (EU) and the European Economic Area (EEA) to continuously donate doses of the Moderna COVID-19 vaccine they purchased as part of the EU`s vaccine strategy on an ongoing basis so that they can be delivered in 2021. This initiative, led by France, Sweden and Norway, is expected to enable the donation of more than 70 million doses of modern COVID-19 vaccine in 2021, including an initial donation of 15 million doses from France and 40 million doses from Germany. .